Two Multi-Site Collaborative Studies Highlight the Value of 454 Sequencing Systems for Genotyping Applications
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
454 Life Sciences, a Roche Company has announced promising new results from a multi-site collaborative research study which used the company's Genome Sequencer FLX System to perform HIV drug-resistant mutation detection.
The findings were outlined last month at the International HIV & Hepatitis Virus Drug Resistance Workshop in Dubrovnik, Croatia, and follow only weeks after the results from a similar multi-site research study, which used the company's sequencing technology for high-resolution HLA genotyping, were presented at the European Immunogenetics and Histocompatibility Conference in Florence, Italy.
Both double-blinded studies were performed by groups of collaborative research institutions with varying degrees of familiarity with the sequencing technology. The findings of each of the two studies include high-accuracy and concordance across sites. The first study used the Genome Sequencer FLX System to perform ultra-deep targeted
resequencing to detect rare HIV variants across the same samples at 11 research institutions.
“The detection of the full range of mutant HIV variants in a sample, also known as viral quasispecies, is is expected to be important for management of drug- resistant HIV-1 infections and the choice of combination antiretroviral therapy,” explained Martin Daeumer, Study Lead and Laboratory Head of Infectious Disease at the Institute of Immunology and Genetics in Kaiserslautern Germany.
“We found that the 454 System’s deep sequencing method enabled the detection of both common viral variants and those undetected by standard population sequencing, with high intra- and inter- laboratory consistency.”
The findings were outlined last month at the International HIV & Hepatitis Virus Drug Resistance Workshop in Dubrovnik, Croatia, and follow only weeks after the results from a similar multi-site research study, which used the company's sequencing technology for high-resolution HLA genotyping, were presented at the European Immunogenetics and Histocompatibility Conference in Florence, Italy.
Both double-blinded studies were performed by groups of collaborative research institutions with varying degrees of familiarity with the sequencing technology. The findings of each of the two studies include high-accuracy and concordance across sites. The first study used the Genome Sequencer FLX System to perform ultra-deep targeted
resequencing to detect rare HIV variants across the same samples at 11 research institutions.
“The detection of the full range of mutant HIV variants in a sample, also known as viral quasispecies, is is expected to be important for management of drug- resistant HIV-1 infections and the choice of combination antiretroviral therapy,” explained Martin Daeumer, Study Lead and Laboratory Head of Infectious Disease at the Institute of Immunology and Genetics in Kaiserslautern Germany.
“We found that the 454 System’s deep sequencing method enabled the detection of both common viral variants and those undetected by standard population sequencing, with high intra- and inter- laboratory consistency.”
